MannKind resumes trading; shares +131.6% AH

|About: MannKind Corporation (MNKD)|By:, SA News Editor

MannKind (MNKD) investors are quite happy an FDA panel has recommended approving the use of Afrezza to treat both type 1 and type 2 diabetes.

Shares have made new 52-week highs.